ClinicalTrials.gg
Not yet recruitingNCT07441408Updated Oct 30, 2026

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

A Phase 3 interventional study of BMS-986278 in Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb. Not yet recruiting at 275 sites in 27 countries. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Updated Oct 30, 20269 sites added9 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,380
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Pulmonary Fibrosis with a site in China — 14 open to participants now, 18 under way, 4 of them phase 3. Pulmonary Fibrosis · China.

Planned enrollment
Largest of 30
2,380 · median 146
Started
2026
with 2 others
Phase 3
7 of 40
1 open now
Primary completion
2029-11
later than 17 of 17 live
Registered
37th of 40
by date
Lead sponsor
4 of 40
Bristol-Myers Squibb

Among the 40 studies in Pulmonary Fibrosis with a site in China, this one has the largest planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 3, reaches primary completion later than 17 of the 17 other live ones, and was the 37th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

14 of the 40 studies in Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

03

Conditions studied

  • Pulmonary Fibrosis

Keywords

  • LPA1 receptor antagonist
  • Idiopathic pulmonary fibrosis
  • Progressive pulmonary fibrosis
  • Long-term extension
  • IPF
  • PPF
  • IM027068
  • IM0271015
  • Follow up
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of in either IM027068 or IM0271015.

Exclusion criteria

Exclusion Criteria:

  • Any disease/condition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation.
  • Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015.
  • Exhibit symptoms of heart failure at rest.
  • History of lung reduction surgery or lung transplant.
  • Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single-drug therapy that now requires multi-drug therapy.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,380 participants (estimated)

Study arms

  • Experimental
    BMS-986278 Arm

    Drug: BMS-986278

Interventions

  • Specified dose on specified days

    Also known as: Admilparant

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Week 100

  2. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to Week 100

  3. Number of Participants With AEs leading to Discontinuation

    Time frame: Up to Week 100

  4. Number of Participants With AEs leading to Deaths

    Time frame: Up to Week 100

  5. Number of Participants With Clinically Significant Laboraty Abnormalities

    Time frame: Up to Week 100

  6. Number of Participants With Clinically Significant Electocardiogram (ECG) Abnormalities

    Time frame: Up to Week 100

  7. Number of Participants With Clinically Significant Vital Sign Abnormalities

    Time frame: Up to Week 100

07

Study locations

275 sites
  • Local Institution - 0113
    Birmingham, Alabama 35294, United States
    • Site 0113 · Contact
  • Local Institution - 0111
    Ocala, Florida 34471, United States
    • Site 0111 · Contact
  • Local Institution - 0119
    Philadelphia, Pennsylvania 19140-5103, United States
    • Site 0119 · Contact
  • Local Institution - 0013
    Florida, Vicente López, Buenos Aires 1602, Argentina
    • Site 0013 · Contact
  • Local Institution - 0014
    Mar del Plata, Buenos Aires 7600, Argentina
    • Site 0014 · Contact
  • Local Institution - 0007
    Quilmes, Buenos Aires 1878, Argentina
  • Local Institution - 0009
    San Juan Bautista, Buenos Aires 1888, Argentina
    • Site 0009 · Contact
  • Local Institution - 0003
    Mar del Plata, B 7600, Argentina
    • Site 0003 · Contact
  • Local Institution - 0001
    Córdoba, Córdoba Province X5003DCE, Argentina
    • Site 0001 · Contact
  • Local Institution - 0005
    CABA, Distrito Federal C1425FVH, Argentina
    • Site 0005 · Contact
  • Local Institution - 0002
    Godoy Cruz, Mendoza Province 5501, Argentina
    • Site 0002 · Contact
  • Local Institution - 0011
    Mendoza, M 5500, Argentina
    • Site 0011 · Contact
  • Local Institution - 0015
    Rosario, S 2000, Argentina
    • Site 0015 · Contact
  • Local Institution - 0012
    San Miguel de Tucumán, Tucumán Province T4000JCU, Argentina
    • Site 0012 · Contact
  • Local Institution - 0010
    Buenos Aires, C1056ABI, Argentina
    • Site 0010 · Contact
  • Local Institution - 0004
    Buenos Aires, C1426ABP, Argentina
    • Site 0004 · Contact
  • Local Institution - 0016
    CABA, 4190, Argentina
    • Site 0016 · Contact
  • Local Institution - 0006
    Mendoza, 5500, Argentina
    • Site 0006 · Contact
  • Local Institution - 0008
    Santa Fe, 3000, Argentina
    • Site 0008 · Contact
  • Local Institution - 0287
    Camperdown, New South Wales 2050, Australia
    • Site 0287 · Contact
  • Local Institution - 0290
    Chermside, Queensland 4032, Australia
    • Site 0290 · Contact
  • Local Institution - 0291
    Greenslopes, Queensland 4120, Australia
    • Site 0291 · Contact
  • Local Institution - 0293
    South Brisbane, Queensland 4101, Australia
    • Site 0293 · Contact
  • Local Institution - 0289
    Adelaide, South Australia 5000, Australia
    • Site 0289 · Contact
  • Local Institution - 0288
    Frankston, Victoria 3199, Australia
  • Local Institution - 0285
    Murdoch, Western Australia 6150, Australia
    • Site 0285 · Contact
  • Local Institution - 0292
    Nedlands, Western Australia 6009, Australia
    • Site 0292 · Contact
  • Local Institution - 0286
    Melbourne, 3128, Australia
    • Site 0286 · Contact
  • Local Institution - 0284
    Wentworthville, NSW2145, Australia
    • Site 0284 · Contact
  • Local Institution - 0249
    Yvoir, Namur 5530, Belgium
    • Site 0249 · Contact
  • Local Institution - 0252
    Leuven, Vlaams-Brabant 3000, Belgium
    • Site 0252 · Contact
  • Local Institution - 0248
    Brussels, 1200, Belgium
    • Site 0248 · Contact
  • Local Institution - 0251
    Kortrijk, 8500, Belgium
    • Site 0251 · Contact
  • Local Institution - 0250
    Liège, 4000, Belgium
    • Site 0250 · Contact
  • Local Institution - 0086
    Belo Horizonte, Minas Gerais 30130-100, Brazil
    • Site 0086 · Contact
  • Local Institution - 0031
    Belo Horizonte, Minas Gerais 30430-142, Brazil
  • Local Institution - 0194
    Barra Mansa, Rio de Janeiro 27323-240, Brazil
    • Site 0194 · Contact
  • Local Institution - 0027
    Porto Alegre, Rio Grande do Sul 90160-092, Brazil
    • Site 0027 · Contact
  • Local Institution - 0028
    Porto Alegre, Rio Grande do Sul 9050-170, Brazil
    • Site 0028 · Contact
  • Local Institution - 0032
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
    • Site 0032 · Contact
  • Local Institution - 0030
    Blumenau, Santa Catarina 89030-100, Brazil
    • Site 0030 · Contact
  • Local Institution - 0033
    Botucatu, São Paulo 18618-687, Brazil
  • Local Institution - 0026
    Santo André, São Paulo 09060-870, Brazil
    • Site 0026 · Contact
  • Local Institution - 0193
    Rio de Janeiro, 20551-030, Brazil
    • Site 0193 · Contact
  • Local Institution - 0025
    Santo André, 09190-510, Brazil
    • Site 0025 · Contact
  • Local Institution - 0066
    São Paulo, 01323-020, Brazil
    • Site 0066 · Contact
  • Local Institution - 0192
    São Paulo, 04023-062, Brazil
    • Site 0192 · Contact
  • Local Institution - 0166
    Sherwood Park, Alberta T8H 0N2, Canada
    • Site 0166 · Contact
  • Local Institution - 0165
    Vancouver, British Columbia V5Z 1M9, Canada
    • Site 0165 · Contact
  • Local Institution - 0168
    Vancouver, British Columbia V6Z 1Y6, Canada
    • Site 0168 · Contact
  • Local Institution - 0167
    Burlington, Ontario L7N 3V2, Canada
    • Site 0167 · Contact
  • Local Institution - 0170
    Hamilton, Ontario L8N 4A6, Canada
    • Site 0170 · Contact
  • Local Institution - 0163
    Owen Sound, Ontario N4K 6M9, Canada
    • Site 0163 · Contact
  • Local Institution - 0169
    Toronto, Ontario M5T 3A9, Canada
  • Local Institution - 0171
    Greenfield Park, Quebec J4V 2H1, Canada
  • Local Institution - 0172
    Montreal, Quebec H2X 1R9, Canada
    • Site 0172 · Contact
  • Local Institution - 0164
    Trois-Rivières, Quebec G8T 7A1, Canada
    • Site 0164 · Contact
  • Local Institution - 0173
    Trois-Rivières, Quebec G9S4P3, Canada
  • Local Institution - 0054
    Concepción, Biobio 4030000, Chile
    • Site 0054 · Contact
  • Local Institution - 0029
    Talcahuano, BI 4260000, Chile
    • Site 0029 · Contact
  • Local Institution - 0052
    Curicó, Maule Region 3340000, Chile
    • Site 0052 · Contact
  • Local Institution - 0051
    Talca, Maule Region 3466706, Chile
    • Site 0051 · Contact
  • Local Institution - 0053
    Santiago, Santiago Metropolitan 7620157, Chile
    • Site 0053 · Contact
  • Local Institution - 0055
    Santiago, Santiago Metropolitan 7750495, Chile
    • Site 0055 · Contact
  • Local Institution - 0050
    Quillota, Valparaiso 2260000, Chile
    • Site 0050 · Contact
  • Local Institution - 0057
    Viña del Mar, Valparaiso 2531172, Chile
    • Site 0057 · Contact
  • Local Institution - 0563
    Hefei, AH 230022, China
    • Site 0563 · Contact
  • Local Institution - 0569
    Hefei, Anhui 230031, China
    • Site 0569 · Contact
  • Local Institution - 0555
    Beijing, Beijing Municipality 100020, China
    • Site 0555 · Contact
  • Local Institution - 0558
    Beijing, Beijing Municipality 100050, China
    • Site 0558 · Contact
  • Local Institution - 0538
    Beijing, Beijing Municipality 100730, China
    • Site 0538 · Contact
  • Local Institution - 0557
    Shenzhen, GD 518116, China
    • Site 0557 · Contact
  • Local Institution - 0543
    Guangzhou, Guangdong 510120, China
    • Site 0543 · Contact
  • Local Institution - 0553
    Guangzhou, Guangdong 510515, China
    • Site 0553 · Contact
  • Local Institution - 0561
    Shenzhen Shi, Guangdong 518020, China
    • Site 0561 · Contact
  • Local Institution - 0539
    Zhengzhou, Henan 450000, China
    • Site 0539 · Contact
  • Local Institution - 0567
    Zhengzhou, Henan 450052, China
    • Site 0567 · Contact
  • Local Institution - 0544
    Shijiazhuang, HE 050051, China
    • Site 0544 · Contact
  • Local Institution - 0568
    Yichang Shi, HE 443099, China
    • Site 0568 · Contact
  • Local Institution - 0556
    Wuhan, Hubei 430002, China
    • Site 0556 · Contact
  • Local Institution - 0549
    Changsha, Hunan 410011, China
    • Site 0549 · Contact
  • Local Institution - 0573
    Suzhou, Jiangsu 215008, China
    • Site 0573 · Contact
  • Local Institution - 0570
    Wuxi, Jiangsu 214023, China
    • Site 0570 · Contact
  • Local Institution - 0551
    Shenyang, Liaoning 110001, China
    • Site 0551 · Contact
  • Local Institution - 0554
    Shenyang, Liaoning 110044, China
    • Site 0554 · Contact
  • Local Institution - 0541
    Chengdu, SC 610041, China
    • Site 0541 · Contact
  • Local Institution - 0548
    Shandong, Shandong 250012, China
    • Site 0548 · Contact
  • Local Institution - 0575
    Shanghai, Shanghai Municipality 200032, China
    • Site 0575 · Contact
  • Local Institution - 0572
    Shanghai, Shanghai Municipality 200233, China
  • Local Institution - 0550
    Chengdu, Sichuan 610015, China
    • Site 0550 · Contact
  • Local Institution - 0547
    Tianjin, Tianjin Municipality 300052, China
    • Site 0547 · Contact
  • Local Institution - 0577
    Tianjin, TJ 300222, China
    • Site 0577 · Contact
  • Local Institution - 0574
    Hangzhou, Zhejiang 310009, China
    • Site 0574 · Contact
  • Local Institution - 0576
    Hangzhou, Zhejiang 310016, China
    • Site 0576 · Contact
  • Local Institution - 0571
    Ningbo, Zhejiang 315010, China
    • Site 0571 · Contact
  • Local Institution - 0552
    Hangzhou, ZJ 310006, China
    • Site 0552 · Contact
  • Local Institution - 0540
    Hohhot, 010010, China
    • Site 0540 · Contact
  • Local Institution - 0559
    Lanzhou, 730000, China
    • Site 0559 · Contact
  • Local Institution - 0542
    Nanjing, 210008, China
    • Site 0542 · Contact
  • Local Institution - 0566
    Shanghai, 200040, China
    • Site 0566 · Contact

Showing the first 100 of 275 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Nov 2029, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 2, 2026
StartEst.
Dec 16, 2026
Primary completionEst.
Nov 22, 2029
CompletionEst.
Mar 30, 2030
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 9 sites removed
Show 9 added (7 South Korea, 1 Germany, 1 Spain)
  • Local Institution - 0179 · Coswig, Germany
  • Local Institution - 0207 · Bucheon-si, South Korea
  • Local Institution - 0206 · Goyang-si, South Korea
  • Local Institution - 0201 · Suwon, South Korea
  • Local Institution - 0198 · Haeundae-gu, South Korea
  • Local Institution - 0199 · Seoul, South Korea
  • Local Institution - 0200 · Seoul, South Korea
  • Local Institution - 0203 · Dong-gu, Ulsan, South Korea
  • Local Institution - 0073 · Barcelona, Spain
Show 9 removed
  • Local Institution - 0179 · Coswig, Germany
  • Local Institution - 0203 · Ulsan, South Korea
  • Local Institution - 0206 · Goyang-si, South Korea
  • Local Institution - 0200 · Seoul, South Korea
  • Local Institution - 0207 · Bucheon-si, South Korea
  • Local Institution - 0198 · Busan, South Korea
  • Local Institution - 0199 · Seoul, South Korea
  • Local Institution - 0201 · Suwon, South Korea
  • Local Institution - 0073 · Girona, Spain
Oct 30, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • Local Institution - 0169 · Toronto, CanadaContact removed (no phone or email listed)
  • Local Institution - 0048 · Bogotá, ColombiaContact removed (no phone or email listed)
  • Local Institution - 0270 · Kolkata, IndiaContact removed (no phone or email listed)
  • Local Institution - 0275 · Nagpur, IndiaContact removed (no phone or email listed)
  • Local Institution - 0063 · Lima, PeruContact removed (no phone or email listed)
  • Local Institution - 0062 · Piura, PeruContact removed (no phone or email listed)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    9 sites added, 9 sites removed
    Show 9 added (7 South Korea, 1 Germany, 1 Spain)
    • Local Institution - 0179 · Coswig, Germany
    • Local Institution - 0207 · Bucheon-si, South Korea
    • Local Institution - 0206 · Goyang-si, South Korea
    • Local Institution - 0201 · Suwon, South Korea
    • Local Institution - 0198 · Haeundae-gu, South Korea
    • Local Institution - 0199 · Seoul, South Korea
    • Local Institution - 0200 · Seoul, South Korea
    • Local Institution - 0203 · Dong-gu, Ulsan, South Korea
    • Local Institution - 0073 · Barcelona, Spain
    Show 9 removed
    • Local Institution - 0179 · Coswig, Germany
    • Local Institution - 0203 · Ulsan, South Korea
    • Local Institution - 0206 · Goyang-si, South Korea
    • Local Institution - 0200 · Seoul, South Korea
    • Local Institution - 0207 · Bucheon-si, South Korea
    • Local Institution - 0198 · Busan, South Korea
    • Local Institution - 0199 · Seoul, South Korea
    • Local Institution - 0201 · Suwon, South Korea
    • Local Institution - 0073 · Girona, Spain
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Local Institution - 0169 · Toronto, CanadaContact removed (no phone or email listed)
    • Local Institution - 0048 · Bogotá, ColombiaContact removed (no phone or email listed)
    • Local Institution - 0270 · Kolkata, IndiaContact removed (no phone or email listed)
    • Local Institution - 0275 · Nagpur, IndiaContact removed (no phone or email listed)
    • Local Institution - 0063 · Lima, PeruContact removed (no phone or email listed)
    • Local Institution - 0062 · Piura, PeruContact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07441408
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Dec 16, 2026 (estimated)
Primary completion
Nov 22, 2029 (estimated)
Completion
Mar 30, 2030 (estimated)
Last update
Oct 30, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Admilparant

Start the discussion